DPYSL4 Antibody Blocking Peptide

Novus Biologicals | Catalog # NBP2-11055PEP

Novus Biologicals
Loading...

Key Product Details

Source

Synthetic

Applications

Antibody Competition
Loading...

Product Specifications

Description

Synthetic peptide corresponding to amino acids 509-527 of human CRMP3.

NCBI Accession #NP_006417.2

Source: Synthetic

Amino Acid Sequence: PAKPGSGTQARASCSGKIS

Purity

>85%, by HPLC

Application Notes

This peptide is useful as a blocking peptide for NBP2-11055.

For further blocking peptide related protocol, click here.

Protein / Peptide Type

Antibody Blocking Peptide

Formulation, Preparation, and Storage

NBP2-11055PEP
Formulation Sodium Bicarbonate buffer, pH 8.00 containing up to 10% DMSO
Concentration 2.5 mg/ml
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -20C. Avoid freeze-thaw cycles.

Background: DPYSL4

Collapsin response mediator proteins (CRMPs) specify axon/dendrite fate and axonal growth of neurons through protein-protein interactions. Collapsing mediated response proteins (CRMPs) form homo- and hetero tetramers and facilitate neuron guidance, growth and polarity. It is abundantly expressed in brain and regulate neurite outgrowth. The CRMP family consists of 5 subtypes (CRMP1-5) and are also known as dihydroxypyrimindinase 1-5 (DRP1-5). The CRMPs promotes microtubule assembly and is required for Sema3A-mediated growth cone collapse and also plays a role in synaptic signaling through interactions with calcium channels. CRMP2 protein regulates endocytosis where two proteins MICAL-L1 and EHD1 are important regulatory proteins that control key endocytotic transport steps. CRMP2 interacts with MICAL-L1 in non-neuronal cells (1). CRMP2 interacts with tubulin dimers and kinesin and negatively regulates s dynein-based transport in neuronal cells (2). The mammalian target of rapamycin (mTOR)is an important regulator of neuronal development and function. mTOR inhibitor, rapamycin regulates neuronal polarity by suppressing the expression of Tau and CRMP2 via mTOR effector 70-kDa ribosomal protein S6 kinase (p70S6K)p70 (2). It is suggested that abnormal activation of CDK5 is associated with neurodegeneratative disorders and it disrupts mature neuronal circuitries and neurogenesis. CDK5 and other kinases hyper-phosphorylate down-stream targets of these kinases in brain such as doublecortin, nestin, and CRMP2 (2). This gene has been implicated in multiple neurological disorders, and hyperphosphorylation of the encoded protein may play a key role in the development of Alzheimer's disease. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. DRP4-selective antibodies were generated against peptides form unique region near C-terminus of DRP4 protein with in aa 508-527. The epitope is conserved in several other species beside human but was unique to DRP4. The DRP4 antibodies are affinity purified over immobilized antigen based affinity chromatography and fully characterized for their listed applications and cross reactivity.

Alternate Names

CRMP-3, CRMP3Collapsin response mediator protein 3, dihydropyrimidinase-like 4, dihydropyrimidinase-related protein 4, DRP-4UNC33-like phosphoprotein 4, ULIP4ULIP-4

Gene Symbol

DPYSL4

Additional DPYSL4 Products

Product Documents for DPYSL4 Antibody Blocking Peptide

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices for DPYSL4 Antibody Blocking Peptide

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Customer Reviews for DPYSL4 Antibody Blocking Peptide

There are currently no reviews for this product. Be the first to review DPYSL4 Antibody Blocking Peptide and earn rewards!

Have you used DPYSL4 Antibody Blocking Peptide?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for DPYSL4 Antibody Blocking Peptide (NBP2-11055PEP):

Antibody Competition Protocol for DPYSL4 Protein (NBP2-11055PEP):
In this assay the antigen binding sites (Fab) of a particular antibody is allowed to bind to homologous antigenic peptide in several hundred molar excess ratio of immunoglobulin to peptide. Since the antigenic peptide has higher affinity for Fab site than the full length native proteins, the antigen binding site is blocked thus antibodies are unable to bind to the specific sites on either native, partial denatured or completely denature antigen on sections, in solution or on membrane blots.

Before starting, standardize the conditions for Western blot, immunoprecipitation or immunohistochemistry using the relevant antibody. Conditions include: volume of antibody used; dilution factor, final volume, incubation time, washing conditions etc.Once conditions have been standardized, repeat the same protocol in duplicate using blocked and unblocked antibody.

Begin the competition assay by preparing the blocked antibody-peptide solution:

1. Take the same volume of antibody as previously standardized. Let us assume 10 uL in 15 mL.
2. Add approximately 1:200 moles of excess peptide (peptides are generally 2200 dalton). This will be equivalent of approximately 60-70ul of peptide solution (original peptide concentration is 2.5mg/ml).
3. Mix 10 uL of antibody with 60-70 uL of peptide and make up the volume to 200 uL using DiluOBuffer.

Compare the above blocked antibody-peptide solution with control antibody:

1. Take same amount of antibody as used in the blocked antibody-peptide solution and add 60-70 ul of PBS and make up the volume to 200 ul using DiluOBuffer.
2. Once both blocked antibody-peptide solution and the control antibody solution have been made, incubate both solutions at 4 degrees C overnight on a rotating mixer. Centrifuge both tubes at 12,000-14000 xg for 1-2 minute at 4 degrees C. A small amount of precipitate may accumulate in the blocked antibody-peptide solution due to antibody-antigen complex formation. If this occurs, carefully remove the precipitate and use only the supernatant.
3. Dilute both solutions in 1X DiluOBuffer to the final dilution volume of 15 mL. The antibody-peptide solution will not give any labeling or will have significantly reduced labeling while the Control Antibody solution should provide standard results.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes
Loading...